Skip to content

Application of a Fasting-mimicking Diet in Obese Patients With Periodontitis Stage III-IV

Application of a Fasting-mimicking Diet in Obese Patients With Periodontitis Stage III-IV

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07549633
Enrollment
40
Registered
2026-04-24
Start date
2026-06-01
Completion date
2027-12-01
Last updated
2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis (Stage 3), Periodontitis Stage IV

Keywords

non surgical treatment, periodontitis, fasting mimicking diet, systemic response

Brief summary

This study will evaluate whether a fasting-mimicking diet (FMD) can improve the systemic and periodontal response to non-surgical periodontal treatment in obese adults with severe periodontitis. Periodontitis is a serious inflammatory disease that damages the tissues supporting the teeth and may also contribute to inflammation elsewhere in the body. Obesity is also associated with increased systemic inflammation, which may worsen periodontal disease and affect treatment outcomes. In this pilot randomized cross-over clinical trial, eligible participants will receive full-mouth non-surgical periodontal therapy and will be assigned either to an FMD group or to a control group continuing their usual diet. The FMD will be administered in three 5-day cycles around the periodontal treatment period. After a wash-out period, the groups will switch interventions. The study will assess whether FMD can reduce systemic inflammation, measured primarily by serum C-reactive protein (CRP), and improve periodontal healing after treatment. Additional outcomes include clinical periodontal measurements, inflammatory markers in gingival crevicular fluid, and changes in oral and gut microbiota. Findings from this study will help determine the feasibility of this dietary approach and provide preliminary data for a larger clinical trial.

Detailed description

Periodontitis is a chronic, biofilm-associated inflammatory disease that leads to destruction of the tooth-supporting tissues and may contribute to systemic inflammation. Obesity is also characterized by a heightened inflammatory burden and may adversely influence periodontal disease severity and treatment response. Although non-surgical periodontal therapy is effective in reducing periodontal inflammation, the short- and medium-term systemic inflammatory response after treatment may vary between individuals. Nutritional strategies that can modulate inflammation may therefore represent a promising adjunctive approach in periodontal care. Previous evidence suggests that dietary restriction regimens may improve periodontal parameters and reduce local and systemic inflammatory burden; however, robust human trials remain limited, particularly in obese individuals with severe periodontitis. In addition, fasting-mimicking diet (FMD) protocols have shown beneficial effects on inflammatory and metabolic pathways and may influence both host response and microbial ecology. No clinical trial has specifically investigated the effects of FMD in obese patients with severe periodontitis. This study is designed as a pilot, randomized, cross-over clinical trial to investigate whether a fasting-mimicking diet can modify the systemic and periodontal response to non-surgical periodontal therapy in obese adults with stage III-IV periodontitis. The clinical phase will be carried out at Akdeniz University, while laboratory analyses will be performed at King's College London. After baseline assessment, participants will receive standardized step 1 and step 2 periodontal treatment, including oral hygiene instruction, risk-factor control, and full-mouth supra- and subgingival professional mechanical plaque removal. Residual pockets will be re-instrumented during follow-up according to the study schedule. Participants will be allocated to one of two study sequences. In the intervention phase, participants assigned to the test condition will follow three cycles of a 5-day fasting-mimicking diet administered around the periodontal treatment period, while participants in the control condition will continue their usual diet. After a wash-out period, the two groups will cross over, allowing each participant to contribute data under both dietary conditions. Because masking of diet allocation is not feasible, the study is designed with blinding of the outcome assessor and statistician. Randomization and allocation concealment will be centrally organized. Compliance with the dietary intervention will be monitored using daily diet questionnaires, and adverse events will be recorded throughout the study period. The study will evaluate the biological and clinical effects of FMD using an integrated approach. Systemic inflammation will be assessed primarily through serum C-reactive protein measurements. Local inflammatory response will be examined using gingival crevicular fluid biomarkers, including inflammatory cytokines and matrix metalloproteinase-8. In addition, subgingival plaque and stool samples will be analyzed to explore whether the intervention is associated with measurable changes in oral and gut microbiota composition and function. Clinical periodontal outcomes and patient-reported measures will also be collected longitudinally. This pilot trial is intended to generate preliminary evidence on feasibility, adherence, biological effect size, and outcome variability, thereby informing the design and sample size calculation of a future larger-scale trial

Interventions

DIETARY_SUPPLEMENTFast mimicking diet group

Participants assigned to this intervention will undergo standard non-surgical periodontal therapy and will receive a fasting-mimicking diet (FMD) in three 5-day cycles administered around the treatment period. The FMD is a plant-based, calorie-restricted dietary program composed of foods generally recognized as safe, including vegetable-based soups, energy bars, energy drinks, cracker snacks, olives, herbal teas, and supplements. The regimen provides approximately 1,100 kcal on day 1 and approximately 750 kcal per day on days 2 to 5.

Participants assigned to this intervention will undergo standard non-surgical periodontal therapy and will continue their usual diet without receiving the fasting-mimicking diet during the assigned study phase.

Sponsors

Akdeniz University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Due to the nature of the dietary intervention, participants and treating clinicians cannot be blinded. However, clinical outcome assessors and the statistician will remain blinded to treatment allocation until completion of the analysis.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-70-year-old patients, * Severe Periodontitis (Stages III-IV), * Systemically healthy, * Overweight (body mass index - BMI \> 30 kg/m2), * Absence of hopeless teeth, acute dental conditions, endo-perio lesions and necrotising periodontal diseases, * Minimum of 20 teeth present.

Exclusion criteria

* Current smokers, * Pregnant women, * Patients drinking more than 20 units of alcohol weekly, * Taking medications including systemic anti-inflammatory medication within 3 months of the study, * Periodontal treatment and/or systemic antibiotics intake within preceding 3 months * Denture wearer/presence of dental implants, * Significant food allergies and/or special dietary requirements which would make the subject unable to consume the food provided.

Design outcomes

Primary

MeasureTime frameDescription
Serum CRP valuesat 90- and 360 days post-treatmentCRP level will be evaluated biochemically

Secondary

MeasureTime frameDescription
Serum CRP valuesbaseline, 1 day post-treatment, 7 days post-treatment, 45 days post-treatment, 180 days post-treatment, 225 days post-treatment, 270 days post-treatment
Analysis of inflammatory cytokines in GCFbaseline, 1 day post-treatment, 7 days post-treatment, 45 days post-treatment, 180 days post-treatment, 225 days post-treatment, 270 days post-treatment
Analysis of sub-gingival plaque samplesbaseline, 90 days post-treatment, 180 days post-treatment and 360 days post-treatmentRelative abundance of selected periodontal pathogens in sub-gingival plaque samples
Patients reported quality of life measurementsbaseline, 90 days post-treatment, 180 days post-treatment and 360 days post-treatmentPatients' outcomes will be assessed by Oral Health Impact Profile-14 (OHIP-14) questionnaire which is used to evaluate the impact oral health (including functional limitations, pain, physiological discomfort, physical disability, social disability, sense of taste, diet unsatisfactory and handicap) on person's life. The Oral Health Impact Profile-14 (OHIP-14) was designed to assess patients' perception of the impact of oral disorders on their quality of life (QoL).
Analysis of stool samplesBaseline and at 90 days post-treatment, 180 days post-treatment and 360 days post-treatmentChanges in gut microbiome composition in stool samples

Countries

Turkey (Türkiye)

Contacts

CONTACTİpek Özgü
ipekozgu7@gmail.com+90 545 525 83 08
STUDY_DIRECTORLuigi Nibali, Prof. Dr.

King's College London, Guy's Hospital

PRINCIPAL_INVESTIGATORKemal Üstün, Prof. Dr.

Akdeniz University

PRINCIPAL_INVESTIGATORMükerrem Hatipoğlu, Prof. Dr.

Akdeniz University

STUDY_DIRECTORGiuseppe Mainas, Dr.

King's College London, Guy's Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026